RECRUITING

Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer

Conditions

Pancreatic Cancer Pancreatic ductal adenocarcinoma PDAC Computed tomography CT Questionnaire Survey

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This trial studies how well computed tomography works in diagnosing patients with pancreatic or hepatobiliary cancer. Computed tomography may help researchers predict how patients with pancreatic or hepatobiliary cancer may respond to chemotherapy.

Official Title

Imaging Biomarkers in Pancreatic and Hepatobiliary Cancers

Quick Facts

Study Start:2015-03-09

Study Completion:2026-06-27

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT02361320

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* PANCREATIC CANCER: Histologically confirmed adenocarcinoma of the pancreas * PANCREATIC CANCER: Non-distant metastatic pancreatic cancer that is either * Unresectable locally advanced disease, defined as primary tumor that involves \> 180 degrees of the superior mesenteric artery, celiac axis or any of its branches on CT or MRI, primary tumor that occludes the superior mesenteric vein or portal vein, aorta or inferior vena cava invasion, or superior mesenteric vein invasion below the transverse mesocolon * Borderline resectable disease, defined as primary tumor that involves =\< 180 degrees of the superior mesenteric artery, celiac axis or any of its branches on CT or MRI, primary tumor that involves the superior mesenteric vein causing vein deformity or segmental venous occlusion with a patent vessel above and below suitable for reconstruction, or primary tumor that abuts or encases (\>= 50% of the vessel circumference) a short segment of the common hepatic artery (typically at the gastroduodenal artery origin) * PANCREATIC CANCER: Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1 * PANCREATIC CANCER: Women of childbearing potential (those who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 consecutive months) must agree to practice adequate contraception and to refrain from breast feeding * PANCREATIC CANCER: Patient who has been recommended chemotherapy treatment for pancreatic cancer * PANCREATIC CANCER: Signed study-specific consent form * HEPATOBILIARY CANCER: Diagnosis of * Hepatocellular carcinoma: This may be diagnosed in the following ways: * Pathologically (histologically or cytologically) proven diagnosis of hepatocellular carcinoma (HCC) * At least one solid liver lesion with arterial enhancement and washout on a delayed phase of a multi-phasic CT or MRI in the setting of cirrhosis or chronic hepatitis B or C without cirrhosis * Intrahepatic cholangiocarcinoma: Pathologically (histologically or cytologically) proven diagnosis of intrahepatic cholangiocarcinoma * HEPATOBILIARY CANCER: Patients may have single or multinodular tumors * HEPATOBILIARY CANCER: ECOG PS 0-1 * HEPATOBILIARY CANCER: Women of childbearing potential (those who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 consecutive months) must agree to practice adequate contraception * HEPATOBILIARY CANCER: Prior history of surgical resection, chemotherapy, transarterial chemoembolization (TACE), and/or radiofrequency ablation are allowed * HEPATOBILIARY CANCER: Patients may be enrolled if: * The patient is dispositioned to receive definitive radiotherapy * The patient has received definitive radiotherapy within the past two years and has liver protocol CT or MRI scans before radiotherapy and at first restaging after radiotherapy * HEPATOBILIARY CANCER: Signed study-specific consent form	* Presence of distant metastasis * Patients whose tumors are defined as resectable * Unstable angina or New York Heart Association grade II or greater congestive heart failure * Evidence of fever or acute infection (chronic infection such as hepatitis virus is acceptable) * Coexisting medical condition that would preclude chemotherapy, radiotherapy, or iodine-based contrast enhanced CT scan * Pregnant women with a positive pregnancy test * Inability to comply with study and/or follow-up procedures * Patients with an active second malignancy with the exception of non-melanoma skin cancer

Inclusion Criteria

Exclusion Criteria

* PANCREATIC CANCER: Histologically confirmed adenocarcinoma of the pancreas
* PANCREATIC CANCER: Non-distant metastatic pancreatic cancer that is either
* Unresectable locally advanced disease, defined as primary tumor that involves \> 180 degrees of the superior mesenteric artery, celiac axis or any of its branches on CT or MRI, primary tumor that occludes the superior mesenteric vein or portal vein, aorta or inferior vena cava invasion, or superior mesenteric vein invasion below the transverse mesocolon
* Borderline resectable disease, defined as primary tumor that involves =\< 180 degrees of the superior mesenteric artery, celiac axis or any of its branches on CT or MRI, primary tumor that involves the superior mesenteric vein causing vein deformity or segmental venous occlusion with a patent vessel above and below suitable for reconstruction, or primary tumor that abuts or encases (\>= 50% of the vessel circumference) a short segment of the common hepatic artery (typically at the gastroduodenal artery origin)
* PANCREATIC CANCER: Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1
* PANCREATIC CANCER: Women of childbearing potential (those who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 consecutive months) must agree to practice adequate contraception and to refrain from breast feeding
* PANCREATIC CANCER: Patient who has been recommended chemotherapy treatment for pancreatic cancer
* PANCREATIC CANCER: Signed study-specific consent form
* HEPATOBILIARY CANCER: Diagnosis of
* Hepatocellular carcinoma: This may be diagnosed in the following ways:
* Pathologically (histologically or cytologically) proven diagnosis of hepatocellular carcinoma (HCC)
* At least one solid liver lesion with arterial enhancement and washout on a delayed phase of a multi-phasic CT or MRI in the setting of cirrhosis or chronic hepatitis B or C without cirrhosis
* Intrahepatic cholangiocarcinoma: Pathologically (histologically or cytologically) proven diagnosis of intrahepatic cholangiocarcinoma
* HEPATOBILIARY CANCER: Patients may have single or multinodular tumors
* HEPATOBILIARY CANCER: ECOG PS 0-1
* HEPATOBILIARY CANCER: Women of childbearing potential (those who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 consecutive months) must agree to practice adequate contraception
* HEPATOBILIARY CANCER: Prior history of surgical resection, chemotherapy, transarterial chemoembolization (TACE), and/or radiofrequency ablation are allowed
* HEPATOBILIARY CANCER: Patients may be enrolled if:
* The patient is dispositioned to receive definitive radiotherapy
* The patient has received definitive radiotherapy within the past two years and has liver protocol CT or MRI scans before radiotherapy and at first restaging after radiotherapy
* HEPATOBILIARY CANCER: Signed study-specific consent form

* Presence of distant metastasis
* Patients whose tumors are defined as resectable
* Unstable angina or New York Heart Association grade II or greater congestive heart failure
* Evidence of fever or acute infection (chronic infection such as hepatitis virus is acceptable)
* Coexisting medical condition that would preclude chemotherapy, radiotherapy, or iodine-based contrast enhanced CT scan
* Pregnant women with a positive pregnancy test
* Inability to comply with study and/or follow-up procedures
* Patients with an active second malignancy with the exception of non-melanoma skin cancer

Contacts and Locations

Study Contact

Eugene Koay

CONTACT

713-563-2300

ekoay@mdanderson.org

Principal Investigator

Eugene Koay

PRINCIPAL_INVESTIGATOR

M.D. Anderson Cancer Center

Study Locations (Sites)

M D Anderson Cancer Center

Houston, Texas, 77030

United States

Collaborators and Investigators

Sponsor: M.D. Anderson Cancer Center

Eugene Koay, PRINCIPAL_INVESTIGATOR, M.D. Anderson Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2015-03-09

Study Completion Date2026-06-27

Study Record Updates

Study Start Date2015-03-09

Study Completion Date2026-06-27

Terms related to this study

Keywords Provided by Researchers

Pancreatic cancer
Pancreatic ductal adenocarcinoma
PDAC
Computed tomography
CT
Questionnaire
Survey

Additional Relevant MeSH Terms

Pancreatic Cancer